Indian Markets LIVE ๐Ÿ“Š
162 subscribers
40.8K photos
5 videos
27 files
106K links
Get Live Trading Ideas ๐Ÿ‘‡
https://t.me/TRADEVL
https://t.me/TRADEVL

More info. @ www.valuelevels.in

Disclaimer- Trading with Stoploss is always recommended on any Calls/Tips.
Download Telegram
Defence stocks detonate in Rs 1.8 lakh crore boom. Is a ceasefire on the charts?
https://economictimes.indiatimes.com/markets/stocks/news/defence-stocks-detonate-in-rs-1-8-lakh-crore-boom-is-a-ceasefire-on-the-charts/articleshow/121257999.cms

Defence stocks surged by Rs 1.8 lakh crore following Operation Sindoor, driven by strong government orders and Make-in-India momentum. Key players like IdeaForge, Cochin Shipyard, and HAL saw significant gains. While optimism runs high, experts caution on stretched valuations and potential profit booking, urging investors to maintain valuation discipline amid rising geopolitical and defence budget developments.
These 5 stocks closed crossing above VWAP on May 16
https://economictimes.indiatimes.com/markets/stocks/news/these-5-stocks-closed-crossing-above-vwap-on-may-16/slideshow/121258485.cms

VWAP breakout, Nifty500 stocks, bullish signal, stock rally, IFCI, Container Corporation of India, Angel One, Sapphire Foods, Aditya Birla Sun Life AMC, trading volume
Sun Pharma shares in focus after USFDA nod for next-gen skin disorder device
https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-shares-in-focus-after-usfda-nod-for-next-gen-skin-disorder-device/articleshow/121258513.cms

Sun Pharma shares: The company announced that the USFDA has approved its enhanced PDT system through the agencyโ€™s Real-Time Review Program. This device is used to treat actinic keratoses (AKs) when used alongside LEVULANยฎ KERASTICKยฎ.
Diviโ€™s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?
https://economictimes.indiatimes.com/markets/stocks/news/divis-lab-shares-in-focus-after-q4-pat-surges-26-yoy-should-you-invest/articleshow/121258346.cms

Divi's Laboratories reported a strong Q4FY25, with a 26% YoY increase in net profit to Rs 667 crore and a 12.26% rise in revenue to Rs 2,536 crore. The company also announced a dividend of Rs 30 per share. Brokerage firms have mixed opinions, with Nuvama issuing a 'Buy' rating and Motilal Oswal maintaining a 'Neutral' stance, citing valuation concerns.